Overview

• SPARC shares plunged 19.8% after Sun Pharma disclosed that Phase 2 SOLARES PsO and SOLARES AD studies for Vibozilimod failed to hit predefined PASI and EASI improvement targets by Week 16.
• Sun Pharmaceutical Industries’ stock slipped about 0.47% in response to the trial outcome.
• The psoriasis arm enrolled 263 participants in a randomized, double-blind, placebo-controlled setup that reported no major safety concerns despite missing efficacy goals.
• Sun Pharma will discontinue further atopic dermatitis trials of SCD-044 and partner with SPARC to reassess the compound’s future potential.
• Both companies are now evaluating next steps for Vibozilimod as they realign their specialty drug development strategies.